Purpose: Arteriovenous fistulas and grafts, necessary for hemodialysis, may develop stenoses due to neointimal hyperplasia, which often require percutaneous transluminal angioplasty. Patient and lesion characteristics were evaluated prior to angioplasty and were correlated with 1-and 6-month outcomes. Materials and Methods: This was an observational study of African American hemodialysis patients who presented for angioplasty of a dysfunctional fistula or graft. Clinical outcomes were ascertained from dialysis facilities 1 month and 6 months after angioplasty. One-month clinical success was defined as dialyzer blood flows of 450 mL/min without complications or interval shunt thrombosis, interventions, or loss of access, which was rarely achieved at 6 months. Logistic regression models were used to evaluate associations of clinical variables with outcomes.
Conclusions : La prise d'aspirine et l'hypertension veineuse ont et e associ ees a la r eussite clinique a 1 mois et a la diminution du nombre de complications majeures a 6 mois. De plus amples etudes doiventêtre conduites pour caract eriser les m ecanismes d'action biologiques de l'aspirine et les effets a long terme relatifs a son utilisation pour entretenir l'abord vasculaire. Ó 2019 Canadian Association of Radiologists. All rights reserved.
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End stage renal disease affects >700,000 people per year in the United States, 63% of who receive hemodialysis [1] . Hemodialysis patients need reliable vascular access from an arteriovenous fistula (AVF) or graft (AVG). Vascular access dysfunction is common and increases morbidity, hospitalization, and costs. Access dysfunction is usually caused by neointimal hyperplasia (NH) [2] . Percutaneous transluminal angioplasty (PTA) is an established treatment for neointimal NH, but patency after angioplasty is variable; only 26%e58% of AVFs remain functional without further interventions after 12 months [3] . Past studies have looked at patency in AVF after PTA finding that newer AVF and longer lesion length may be predictors of success [4, 5] . Success after PTA of stenosis of AVF exceeds that in AVG in other studies [6] . A comprehensive study to determine how clinical, anatomic and medicationrelated factors influence PTA is lacking. We therefore sought to evaluate the clinical characteristics of patients undergoing PTA and collect detailed data on the anatomic characteristics of stenotic lesions before and after procedures.
Methods

Data Source and Study Population
This was an observational study of adult hemodialysis patients who presented for PTA of a dysfunctional AVF or AVG at the University of Chicago Medical Center between November 2016-May 2018. This study was approved by the Institutional Review Board of the University of Chicago Medical Center. Patients were excluded if they were found to have AVF or AVG thrombosis at presentation, or if they were unwilling or unable to give consent.
Demographic data, including age, sex, race, weight, height, body mass index, and hemodialysis start date were obtained from medical records. Patients included in this study were all African American as they account for the core of all access procedures performed at the University of Chicago Medical Center. Comorbid conditions collected included: diabetes, hypertension, peripheral vascular disease, coronary artery disease, autoimmune disease, cerebrovascular disease, venous thromboembolism, congestive heart failure, tobacco exposure, and history of kidney transplantation. We noted medications in use including warfarin, aspirin, clopidogrel, or any other anticoagulants, as well as HMG-CoA reductase inhibitors (statins), glucocorticoids, and inhibitors of the renin-angiotensinaldosterone cascade. All patients who received clopidogrel also received aspirin, so these were grouped as dual antiplatelet (aspirinþclopidogrel). An exact CHA2DS2-VASc score was calculated for each participant, and this variable was categorized as low (< 3), medium (4e6) and high (> 7) [7] .
Access location was categorized according the type of vascular access (AVG or AVF) and location (radiocephalic, brachiocephalic, or brachiobasilic, or femoral) which was obtained from the records and the imaging reports. Indication for PTA was obtained from the procedure report including: prolonged bleeding, cannulation pain, high venous pressure, low arterial pressure, withdrawal of thrombi, infiltrations, reduced urea clearance, infection, or edema of the arm, neck, or head.
Each participant underwent an angiogram with one or more angioplasty procedures in the Interventional Radiology laboratory at the University of Chicago Medical Center. An angioplasty was performed if it was determined that the venous stenosis was hemodynamically significant and/or greater than 50% by estimate. Details regarding the stenotic lesion characteristics were collected, including number of lesions; location of each lesion (eg, venous outflow, anastomosis, central, within AVG). All pre-and post-procedure images were formally evaluated by an interventional radiologist, who evaluated each stenosis in a single anterior-posterior (AP) plane after the venogram was completed. A segment of normal vein located immediately adjacent and peripheral to the lesion was used as a reference to calculate the percentage of stenosis both before and after PTA. Measurements were made at the completion of the procedure using electronic caliper tool on Philips iSite PACS software (Koninklijke Philips N.V., Amsterdam, The Netherlands). Lesions were classified as long if > 1.0 cm, short if 1.0 cm, and focal if < 1 mm. The intervention details were recorded, including the balloon size and type (standard, cutting, high pressure, drug-coated). Placement of stents, while uncommon, was also recorded.
Outcomes
Clinical outcomes were ascertained from dialysis unit staff at 1 month and 6 months after PTA. Success at 1 month was defined as being able to maintain dialyzer blood flows of 450 mL/min during dialysis, without incurring any of the 9 indications for PTA. Very few patients achieved this level of success at 6 months, requiring a more modest goal for success at 6 months: continued function without thrombosis, repeat angioplasty, surgical revision, or abandonment of the access.
Statistical Analyses
Means and medians were used to summarize distributions of normally and non-normally distributed continuous variables, with Student's t tests, Wilcoxon rank sum tests, Chi-squared, and Fisher's exact tests as appropriate to compare values. Logistic regression was used to evaluate the associations of baseline variables with the 1-month success outcomes as defined. Models for clinical characteristics were constructed as a per-procedure analysis; models for anatomic features were constructed as a per-lesion analysis. Models were adjusted for clustering by patient, allowing calculation of robust standard errors. Multivariable models were adjusted for age, sex, CHA2DS2-VASc score, clopidogrel use and body mass infex, and stratified for AVF vs AVG. Potential covariates for multivariable models were otherwise selected based on Wald tests in univariate models, and multivariable models were developed using stepwise selection, with checking for interactions. All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary NC).
Results
Over the study period, we evaluated 150 stenoses treated during 99 procedures in 82 patients. We studied repeat procedures, if these occurred more than 1 month after the index angioplasty. Nine patients were studied twice and 4 patients were studied 3 times. Patient characteristics are summarized in Table 1 which includes data separated by AVF and AVG.
Mean age of the participants was 56.3 AE 15.1 years; 53.0% were female and 96% were hypertensive. Mean body mass index was 29.3 AE 7.2 kg/m 2 . AVF were present in 72% of patients and AVG in the remainder, with 82.9% of AVF/ AVG located in the upper arm, 12.2% in the forearm, and 4.9% in the thigh. Warfarin use was rare (6.1%), but 42 patients (51.2%) received aspirin, of whom 6 received dual anti-platelet therapy (5 with clopidogrel and one with warfarin). 51.2% received statins, and 36.6% received inhibitors of the renin-angiotensin-aldosterone system. Among 150 stenoses, 71 were in the venous outflow, 23 at the anastomosis, 38 were located centrally, 4 were within-graft, and 14 were located in other locations. The anatomic phenotype of each individual patient is available in the Supplementary Table S1 . There were 52 focal lesions (<1 mm), 72 short lesions (non-focal, 1 cm), and 26 long (>1 cm) lesions. The median pre-PTA stenosis was 56.5% (interquartile range [IQR)] ¼ 46.0%e69.2%); median post-PTA stenosis was 20.1% (IQR ¼ 10.0%e30.0%) for a median change of 36.4% (IQR ¼ 22.1,50).
PTA was considered to be clinically successful at 1 month in 66 (66.7%) of procedures, involving 100/150 stenoses. Clinical success at 1 month was positively associated with use of aspirin (P ¼ .005) and with procedures performed for high venous pressures, as opposed to any other indication (P ¼ .004). No other variables exhibited significant associations with 1 month clinical success ( Table 2 ). The associations of aspirin and high venous pressure were preserved in the multivariable logistic regression models (Table 3) ; a test for interaction between the 2 variables was non-significant
Data were available at 6 months for 120 lesions treated during 81 procedures performed on 67 patients. Minor complications were defined as the clinical symptoms of access dysfunction which required a return for a follow up venogram and PTA. Major complications were defined as an access thrombosis which required a thrombectomy, surgical revision, or loss of access. Additional interventions were required after 47 procedures, of which 37 (45.7%) were repeat angioplasty and ten (12.3%) were interventions for major complications. Seven patients required thrombectomy, 2 required surgical revisions, and one access was abandoned. The distribution of events differed between patients receiving aspirin and those who did not (Table 4 ). Two major complications (both thrombectomies) occurred after 44 procedures on patients who were taking aspirin (4.6%); the other 8 major events were sustained after 37 procedures performed on patients who were not receiving aspirin (21.6%, P ¼ .04). However, repeat angioplasty was more common after procedures performed on patients taking aspirin (56.8% vs 32.4%) then those who were not (P ¼ .03). The distribution of events did not differ significantly according to any other variables, including indication for procedure, anatomic measurements, number of stenoses, or lesion length.
Per Society of Interventional Radiology (SIR) guidelines, angioplasty is considered unsuccessful if, despite the use of high-pressure balloons, there is elastic recoil of the vein such that the stenosis remains >50% [8] . When a stent was placed, we considered this a technical failure of PTA. 150 angioplasty were performed with 5 stent placed in a venous stenosis which gives a technical success rate of PTA of 97%.
Discussion
This study analyzed predictors of patency at 1 month and 6 months after PTA in patients with dysfunctional but patent AVF or AVG. We found that 1 month outcomes defined as clinical success were achieved after 67.0% of procedures, but that more than half of patients required additional interventions over the next 6 months. If patients made it to 1 month with clinical success, they were less likely to need to return for another intervention; however, the benefit did not translate to the 6-month outcome. Most studies that evaluate clinical success after PTA look at outcomes at 3, 6, and 12 months. We choose the 1-month outcome as it gave the nephrologist time to consider either a repeat PTA or surgical referral. The difference between a repeat PTA and access failure at 6 months is relevant to dialysis patients and their providers. Moreover, it is believed that PTA may cause endothelial damage causing vessel wall hypertrophy leading to restenosis and the need for repeat PTA which makes the 1 month outcome relevant [8] .
One month clinical outcomes were better for patients who were on aspirin or whose PTA was performed for high venous pressure. There were no significant associations between 1 month clinical successes and any anatomic features or measurements, including access type. Success at one month was rarely sustained, requiring us to define a lower standard in order to study 6-month success. Six-month outcomes were less likely to be major complications when patients were taking aspirin but did not differ with procedural indication or any anatomic characteristics.
Our primary hypothesis was that the anatomic characteristics of stenotic lesions before and after procedures would predict clinical success. A venous stenosis was determined to be hemodynamically significant by best estimate during the venogram. In general, if a venous stenosis appeared to be greater than 50% a PTA was performed. The actual measurements of the target lesions were done after the procedures and imaged in the AP plane only. The diameter of the adjacent, more peripheral vein, was used as the reference diameter. The percentage of stenosis was defined as the percent diameter reduction relative to the reference vessel. In this analysis we included all measured stenosis in the AP plane that were angioplastied. After the PTA, we measured and found that some of the pre-stenosis measurements were less than 30% which deviates from the SIR standards which define a functionally significant stenosis as 50% reduction in diameter with accompanying hemodynamic or clinical abnormality [9] . The SIR guidelines, however, do acknowledge that the 50% threshold may be of ''limited relevance and needs to be considered in the context of functional and clinical findings'' [9] . It's also possible that some of our lesions which were measured as 30% were in fact greater had we imaged in the orthogonal plane (aka 90 degrees oblique). A comprehensive review of predictors of patency after PTA found only one study with the stenotic lesions described with a measurement [4] . Wu et al measured a biomarker, asymmetrical dimethyarginine, as a predictor of restenosis after Table 3 Associations of aspirin and high venous pressure with 1-month outcomes of angioplasty PTA. In this study, the degree of stenosis was evaluated by 2 orthogonal planes and the greatest degree of stenosis was used for subsequent anatomic measurements [10] . There is ambiguity in the definition of an anatomic venous stenosis. Given the ability of modern interventional techniques to calculate a venous stenosis, future studies are needed to define anatomic criteria for measurement of venous stenosis which predicts success.
Previous studies that have looked at associations between medications and secondary patency of the AVF or AVG have found mixed results [11e13]. The Dialysis Outcomes and Practice Patterns Study (DOPPS) reported that aspirin therapy was associated with better secondary graft patency and angiotensin-converting-enzyme (ACE) inhibitor therapy was associated with better secondary fistula patency [14] . In our study, aspirin but not ACE inhibitors was associated with better outcomes at 1 month. This may be due to the differences in the populations examined in these studies, as we studied primarily African American patients. Also, only 16.9% of DOPPS participants were on aspirin and 18.7% were on ACE inhibitors, whereas in our study 33% of participants were on ACE inhibitors and 59% were on aspirin. Thus the baseline characteristics of the participants in the DOPPS and in our study were different. In the Dialysis Access Consortium studies [15, 16] , clopidogrel and dipyridamole were both associated with modest effects on AVF and AVG respectively. We therefore adjusted for clopidogrel use in our analysis. No patients were receiving dipyridamole.
Our data did not reveal any significant associations between statin use and PTA outcomes. Statins have pleotropic effects shown to improve hemodynamic flow and prevent NH in vascular systems through inhibition of Rho-kinase [17] . Animal models and human studies support use of statins. Simvastatin used before AVF creation decreased expression of matrix-regulating genes (VEGF-A, MMP2, MMP9), resulting in a decrease in venous NH with positive vascular remodeling [18] . In humans, high-dose statin monotherapy has been shown to inhibit Rho-kinase activity and improve endothelial function as measured by flow mediated vasodilation [19] . Simvastatin and folic acid therapy has been shown to prolong AVF survival [20] . A retrospective analysis evaluated 3 different statins on primary AVF outcomes and found that atorvastatin improved the overall primary failure rate of AVF, concluding that the benefit of statins on AVF outcome was a drug-specific, not a class effect, influenced by the type of AVF [21] . Another retrospective trial showed that statins did not decrease the number of stenotic lesions developing in AVF or prolong the interval between PTA procedures [22] . However, a retrospective observational study of 132 PTA procedures in 126 patients found that patients receiving statins had improved primary and secondary patency rates [23] . In a large Taiwanese population study, 9862 pairs of end-stage renal disease (ESRD) patients with new vascular access were matched by age and sex, to evaluate impact of statins, and an 18% risk reduction in the composite end-point of angioplasty and access abandonment was observed in AVF, but not AVG [12] .
We could not demonstrate a relationship between patency rate and access location, in agreement with previous studies, nor did we see any significant differences between outcomes in AVF and AVG, in contrast to other studies. Our data also corroborate the findings of a systemic review by Neuen et al [4] , which found that the degree or location of stenosis before angioplasty was not associated with patency outcomes in any study. We performed meticulous measurements of the vein segment located immediately adjacent and peripheral to the lesion, using this as a reference to calculate the percentage of stenosis both before and after PTA, on the assumption that this represented the native diameter of the segment being treated by angioplasty.
Our primary finding was that aspirin use was associated with improved symptomatic outcomes at 1 month and decreased major complications at 6 months. The mechanism by which aspirin could be contributing to PTA results was beyond the scope of this study. Irreversible inhibition of platelet cyclooxygenase activity and thromboxane formation does not seem a likely explanation for effects upon NH. Another potential mechanism is that aspirin inhibits collagen-induced release of platelet-derived growth factor, ß-thromboglobulin, and thromboxane B2 (TxB2) [24] . Intimal thickening and proliferation of vascular smooth muscle cells are histological features of both late coronary graft occlusion and late restenosis after percutaneous transluminal cardiac angioplasty, and may be associated with platelet-derived growth factor release [25] . The same processes may be occurring in AVFs and AVGs. Aspirin may have a role in prevention of endothelial injury via nitric oxide synthase activity. The nitric oxide-cGMP signaling pathway in endothelial cells is known to be activated by aspirin [26] . Increases in nitric oxide and cGMP might contribute to PTA outcomes by causing an antioxidant effect improving the integrity of the endothelium [27] .
There have been 2 large population studies of anti-platelet agents in ESRD patients. A retrospective evaluation of over 90,000 ESRD patients in the Taiwan National Health Insurance Program were studied to estimate the efficacy of thrombosis prevention and risk of bleeding with different antiplatelet agents and oral anticoagulants. Anti-platelet agents, but not warfarin, reduced the risk of vascular access thrombosis rate, but there was an increased risk of bleeding with clopidogrel and aspirin-dipyridamole [28] . An analysis of 24,847 hemodialysis patients who had vascular access placement from the Society for Vascular Surgery Vascular Quality Initiative showed that primary patency of AVG but not AVF was improved in patients receiving antiplatelet therapy. [29] .
The results of this study can only be concluded for African American patients with ESRD. African Americans are more likely to have an AVG and the need for imaging procedures when compared to other racial groups [30] . African Americans have multiple risk factors which predispose them to cardiac events when compared to white people [31] . Racial disparities affect the outcome of endovascular procedures as African Americans have worse outcomes and the need for re-intervention after arterial endovascular interventions [32] . Aspirin is often prescribed to prevent or treat vascular disease. There is, however, a racial component to the degree of anti-platelet effect from aspirin, and in some studies clopidogrel offers less protection to African Americans than white people [33e35]. There is a racial disparity in vascular access for hemodialysis that requires further investigation and favors a personalized approach to improve access outcomes.
The results of the current study call for a prospective matched study to confirm if aspirin is effective to prevent restenosis of AVF and AVG after PTA. Certain limitations merit discussion. This is an observational study, consisting of a single center with a predominantly African American population, which could limit the generalizability of our findings. Use of aspirin, or any other medications, was based on retrospective review at the time of procedure. We lack data on the duration and the consistency of aspirin exposure over the period of observation. Indications for aspirin were not known, so there could potentially be confounding by indication.
In summary, we found that aspirin use was associated with improved symptomatic outcomes after PTA at 1 month and fewer serious access complications at 6 months in African Americans receiving hemodialysis. Our results imply that patients with AVF or AVG dysfunction may benefit from receiving aspirin prior to PTA. Low-dose aspirin is an inexpensive and safe medication for patients with ESRD, so the risk-benefit ratio of aspirin seems favorable in this setting. Further work would be needed to determine if there are any beneficial effects of aspirin on longer term outcomes, to evaluate whether these findings are observed in non-African American populations, and to investigate potential biologic mechanisms by which aspirin may affect hemodialysis vascular access.
